Shares of Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) were down 3.7% during trading on Monday . The company traded as low as $7.87 and last traded at $7.90, with a volume of 53,897 shares traded. The stock had previously closed at $8.20.

Several research firms have recently issued reports on FOMX. Guggenheim restated a “buy” rating and set a $10.00 target price on shares of Foamix Pharmaceuticals in a research report on Tuesday, May 10th. TheStreet upgraded Foamix Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 2nd. Finally, Zacks Investment Research lowered Foamix Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, May 4th.

The company’s market capitalization is $241.88 million. The stock has a 50-day moving average of $6.95 and a 200-day moving average of $6.58.

Foamix Pharmaceuticals (NASDAQ:FOMX) last released its earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.08. Equities research analysts predict that Foamix Pharmaceuticals Ltd. will post ($0.89) earnings per share for the current fiscal year.

Foamix Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea, impetigo and other skin conditions. The Company operates in the segment of development and commercialization of foam-based formulations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.